Literature DB >> 9201079

Effect of octreotide on human sphincter of Oddi motility following liver transplantation.

F H Weber1, R J Sears, B Kendall, T L Pruett, H A Shaffer, P Yeaton.   

Abstract

The effect of octreotide on sphincter of Oddi motility was investigated in six liver transplant patients, employing percutaneous (through the T-tube tract) manometry. Continuous and simultaneous sphincter of Oddi and duodenal motor activities were recorded before and for 60 min after the administration of octreotide (100 micrograms subcutaneously) and after the injection of cholecystokinin (0.02 microgram/kg intravenously). With octreotide, contraction frequency and basal pressure significantly increased (P < 0.05). This effect lasted more than 60 min, long after octreotide-induced duodenal migrating motor complex phase III activity had ceased. Sphincter of Oddi contraction amplitude and duration were unaffected by octreotide. Subsequent cholecystokinin administration transiently reduced sphincter of Oddi basal pressure and contraction frequency. We conclude that octreotide significantly increases sphincter of Oddi basal pressure and contraction frequency. This effect is distinct from octreotide induction of migrating motor complex phase III activity, persists for a prolonged period, and is inhibited by cholecystokinin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9201079     DOI: 10.1023/a:1018885519918

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

1.  Prevention of pancreatic reactions by bolus somatostatin administration in patients undergoing endoscopic retrograde cholangio-pancreatography and endoscopic sphincterotomy.

Authors:  J M Bordas; V Toledo; F Mondelo; J Rodés
Journal:  Horm Res       Date:  1988

Review 2.  Dysmotility disturbances of the biliary tract: classification, diagnosis, and treatment.

Authors:  W J Hogan; J E Geenen; W J Dodds
Journal:  Semin Liver Dis       Date:  1987-11       Impact factor: 6.115

3.  Effect of somatostatin on the pancreatitis-like biochemical changes due to endoscopic pancreatography: preliminary report.

Authors:  G Tamás; Z Tulassay; J Papp; A Paksy; L Korányi; S Kisfaludy; E Kollin; K Steczek
Journal:  Metabolism       Date:  1978-09       Impact factor: 8.694

Review 4.  Physiology of the human sphincter of Oddi.

Authors:  A Torsoli
Journal:  Endoscopy       Date:  1988-08       Impact factor: 10.093

5.  Action of cholecystokinin and caerulein on the rabbit sphincter of Oddi.

Authors:  J C Sarles; J M Bidart; M A Devaux; C Echinard; A Castagnini
Journal:  Digestion       Date:  1976       Impact factor: 3.216

6.  Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis?

Authors:  K F Binmoeller; A G Harris; R Dumas; C Grimaldi; J P Delmont
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

7.  Somatostatin-containing cells in the extrahepatic biliary tract of humans.

Authors:  H Dancygier; U Klein; U Leuschner; K Hübner; M Classen
Journal:  Gastroenterology       Date:  1984-05       Impact factor: 22.682

8.  A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis.

Authors:  J M Sternlieb; C A Aronchick; J N Retig; M Dabezies; F Saunders; E Goosenberg; A Infantolino; S Ionna; G Maislin; S H Wright
Journal:  Am J Gastroenterol       Date:  1992-11       Impact factor: 10.864

9.  Human fasting and postprandial sphincter of Oddi motility.

Authors:  C S Worthley; R A Baker; J Iannos; G T Saccone; J Toouli
Journal:  Br J Surg       Date:  1989-07       Impact factor: 6.939

10.  Effect of a new somatostatin analogue on pancreatic function in healthy volunteers.

Authors:  E Köhler; C Beglinger; S Dettwiler; I Whitehouse; K Gyr
Journal:  Pancreas       Date:  1986       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.